Related Experiment Videos
Summary
Apheresis for systemic lupus erythematosus (SLE) has evolved from a broad treatment to a niche adjunct therapy. This review examines its history, physiology, and current role in lupus management.
Area of Science:
- Immunology
- Nephrology
- Hematology
Background:
- Apheresis technologies have evolved significantly since the 1960s.
- Initial use of apheresis for systemic lupus erythematosus (SLE) began in 1974.
- Conceptual understanding of apheresis indications in SLE has changed over time.
Observation:
- Once considered a primary treatment for various SLE aspects, apheresis is now a secondary or adjunctive therapy.
- Apheresis has found specific, limited roles within the broader lupus therapeutic landscape.
Findings:
- This article critically reviews the historical development, physiological basis, and rationale for using apheresis in SLE.
- Literature analysis supports a focused application of apheresis in specific SLE patient subsets.
Implications:
- Apheresis is not a universal cure but a specialized tool for select lupus cases.
- Understanding the precise indications for apheresis optimizes its use in the SLE treatment spectrum.